Breast cancer survivors frequently face a cluster of persistent neuropsychiatric symptoms that significantly compromise quality of life after the end of cancer treatment. Difficulties with concentration, debilitating fatigue, insomnia, and emotional changes — frequently described as "brain fog" — may extend for months or years. A new pilot, randomized, double-blind clinical trial led by researchers from the University of California, Irvine (UC Irvine) and Yale University demonstrates that electroacupuncture targeted to specific neuropsychiatric acupoints can produce measurable improvements in the cognitive function of these patients.
CLINICAL TRIAL NUMBERS
Study design
The trial, published in the Journal of the National Cancer Institute, used a double-blind design — both patients and assessors were unaware of group allocation. The 35 participants, all breast cancer survivors with persistent cognitive complaints, were randomized into two arms: the active group received electroacupuncture at acupoints selected specifically for their relationship with neuropsychiatric circuits, while the control group received electroacupuncture at non-specific acupoints, without direct relation to cognitive functions. Sessions were performed weekly over ten weeks.
Cognitive and neurologic results
The results demonstrated a clinically significant difference between groups. In the group that received targeted electroacupuncture, 43% of participants presented measurable improvement in cognitive function, especially in tasks of sustained attention and processing speed. In the control group, only 12.5% reached this level of improvement — a 3.4-fold difference in the rate of therapeutic response.
In addition to the cognitive gains assessed by standardized neuropsychological tests, neuroimaging examinations revealed relevant structural and functional findings. Patients in the active group presented increased gray matter volume in cortical regions associated with attention and executive control. In parallel, favorable changes in functional brain connectivity were identified, correlated with the degree of individual cognitive improvement.
NEUROIMAGING FINDINGS
Reduction of neuroinflammation
One of the most relevant findings of the study was the reduction of neuroinflammation biomarkers in the group that received targeted electroacupuncture. Cancer treatment — including chemotherapy, radiotherapy, and hormone therapy — may induce a chronic inflammatory state in the central nervous system, a mechanism considered one of the main mediators of post-treatment cognitive impairment. The capacity of electroacupuncture to modulate this inflammatory response represents a possible therapeutic mechanism of action with translational relevance.
Safety and tolerability
The safety profile of the treatment was favorable. Electroacupuncture was well tolerated by most participants, with side effects limited to mild and transient reactions at the site of needle insertion. No serious adverse events were recorded in either group — given the small sample (n=35), these safety findings require confirmation in larger studies in oncologic populations. This is particularly relevant for the cancer population, which frequently presents increased sensitivity to therapeutic interventions and polypharmacy.
Significance for clinical practice
The results of this pilot trial, although obtained in a relatively small sample, offer a promising basis for larger-scale confirmatory trials. The research was led by Alexandre Chan, of UC Irvine, with Ding Quan Ng as first author — academic centers of reference in integrative oncology. The fact that the intervention demonstrated efficacy not only in subjective outcomes, but also in objective neurologic markers (neuroimaging and biomarkers), confers robustness to the evidence generated.
For medical acupuncture practice broadly, this study reinforces the importance of careful selection of acupoints based on neurophysiologic rationale, and not only on generic protocols. The integration of electroacupuncture into supportive cancer care, coordinated by the physician, may represent a valuable complementary strategy for a condition that currently has few effective therapeutic options.
Frequently Asked Questions
Electroacupuncture is a modality that combines the insertion of needles at acupoints with the application of microcurrents between pairs of needles. This electrical stimulation allows precise control of frequency and intensity of the stimulus, potentiating the activation of specific neural pathways. In medical practice, it is used when a more intense and reproducible neuromodulatory effect is desired than that obtained with manual manipulation of needles alone.
The study specifically evaluated survivors with persistent cognitive complaints after the end of cancer treatment. The indication should be individualized by the physician, considering the symptom profile, time since treatment, possible local contraindications, and the patient’s general clinical status. Since this is a pilot trial, larger confirmatory trials are needed before broad recommendations.
Founded in 1989 by physicians trained at the University of São Paulo (USP) and specialized in China, CEIMEC is a Brazilian national reference in the teaching and practice of medical acupuncture. With more than 3,000 physicians trained over 35 years, it collaborates with HC-FMUSP and is recognized by the Brazilian Medical College of Acupuncture (CMBA/AMB).
Learn More about this Topic
Related educational articles
Can Cancer Patients Receive Electroacupuncture? Safety Guidelines
Indications, precautions, and contraindications for electroacupuncture use in patients with cancer
Chronic Fatigue: Recognize, Diagnose, and Treat
Understand myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) — a complex neuroimmunological condition, its mechanisms, diagnosis, and therapeutic approaches.
Primary Insomnia: Why You Cannot Sleep — and How to Treat It
Understand chronic insomnia — the most prevalent sleep disorder, its neurobiologic mechanisms, diagnosis, and evidence-based treatments.